ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,123Medicare Part D Prescriptions Filled, Including Refills

Rank: 15 out of 403

$723K Total Retail Price of All Prescriptions

Rank: 16 out of 403

518 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
50% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Connecticut
Lower avg

Schedule Two
Controlled Substances

4% of this provider’s 518 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

6% of this provider’s 518 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 8,935 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

29% of this provider’s prescriptions were for brand-name drugs, compared to an average of 28%.

Prescription Price

$71 was the average price of a prescription from this provider, compared to $72 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Connecticut
AMLODIPINE BESYLATE 523 510 1 4
LEVOTHYROXINE SODIUM 344 293 2 3
SIMVASTATIN 340 294 3 2
PRAVASTATIN SODIUM 284 252 4 14
LISINOPRIL 253 226 5 1
ATORVASTATIN CALCIUM 241 204 6 5
FUROSEMIDE 236 198 7 7
HYDROCHLOROTHIAZIDE 232 231 8 6
WARFARIN SODIUM 228 201 9 12
METFORMIN HCL 217 170 10 8
METOPROLOL TARTRATE 195 172 11 10
OMEPRAZOLE 164 141 12 9
DIOVAN 161 134 13 24
ALENDRONATE SODIUM 125 125 14 26
ALLOPURINOL 123 119 15 31
METOPROLOL SUCCINATE 123 123 15 11
ATENOLOL 120 114 17 13
TRAZODONE HCL 119 119 18 25
BENAZEPRIL HCL 119 106 18 72
MIRTAZAPINE 107 107 20 38
CRESTOR 99 83 21 19
GABAPENTIN 97 90 22 17
LISINOPRIL-HYDROCHLOROTHIAZIDE 92 88 23 29
PAROXETINE HCL 88 73 24 68
LOSARTAN POTASSIUM 85 85 25 21
QUINAPRIL HCL 84 71 26 67
METFORMIN HCL ER 84 81 26 50
FELODIPINE ER 83 68 28 140
TAMSULOSIN HCL 83 73 28 27
LANTUS 80 80 30 54
DONEPEZIL HCL 77 77 31 23
POTASSIUM CHLORIDE 72 72 32 37
ZETIA 71 71 33 59
LABETALOL HCL 69 69 34 188
GLIMEPIRIDE 69 64 34 61
LOVASTATIN 68 55 36 42
PANTOPRAZOLE SODIUM 67 63 37 30
LIPITOR 67 54 37 53
VERAPAMIL ER 60 59 39 98
POLYETHYLENE GLYCOL 3350 59 36 40 60
PROAIR HFA 58 49 41 40
CYMBALTA 55 47 42 43
NEXIUM 55 34 42 18
LEVEMIR FLEXPEN 54 50 44 121
SERTRALINE HCL 54 48 44 20
DIOVAN HCT 53 48 46 69
SPIRIVA 53 52 46 35
FLUOXETINE HCL 52 48 48 57
CITALOPRAM HBR 52 51 48 22
FINASTERIDE 52 52 48 82
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.